专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09278119B2 Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients 有权
标题翻译：前列腺癌的治疗和前列腺癌患者预后的确定方法
公开(公告)号：US09278119B2
公开(公告)日：2016-03-08
申请号：US14128064
申请日：2012-06-28
申请人： Tommy Andersson , Anders Bjartell
发明人： Tommy Andersson , Anders Bjartell
IPC分类号： A61K38/04 , C07K7/00 , A61P35/00 , A61K38/10 , C07K14/475 , G01N33/50 , G01N33/574 , A61K38/08
CPC分类号： A61K38/10 , A61K38/08 , C07K14/475 , G01N33/5088 , G01N33/57434 , G01N2800/52
摘要： The present invention relates to a Wnt5a protein or peptide thereof possessing Wnt5a signaling properties, such as Foxy5, for use in the treatment of prostate cancer, in particular in patients that have undergone or will undergo radical prosteatectomy. The invention also relates to a method for determining a prognosis for a patient having prostate cancer and a kit for performing said method. The method for determining a prognosis for a patient comprises the steps of: evaluating an amount of Wnt5a protein present in at least part of a sample earlier obtained from the patient and determining a sample value corresponding to the evaluated amount; comparing the sample value obtained in step a) with a reference value associated with a reference prognosis; and, if said sample value is higher than said reference value, concluding that the prognosis for said patient is better than said reference prognosis.
摘要翻译：本发明涉及具有Wnt5a信号传导特性的Wnt5a蛋白或其肽，例如Foxy5，用于治疗前列腺癌，特别是在经历或将进行根治性前列腺切除术的患者中。本发明还涉及一种用于确定具有前列腺癌的患者的预后的方法和用于执行所述方法的试剂盒。用于确定患者预后的方法包括以下步骤：评估存在于患者早期获得的样品的至少部分中的Wnt5a蛋白质的量并确定与所述评估量相对应的样品值; 将步骤a）中获得的样品值与参考预后相关的参考值进行比较; 并且如果所述样品值高于所述参考值，则认为所述患者的预后优于所述参考预后。

2. 发明申请

US20140206623A1 TREATMENT OF PROSTATE CANCER AND A METHOD FOR DETERMINING THE PROGNOSIS FOR PROSTATE CANCER PATIENTS 有权
标题翻译：前列腺癌的治疗方法及确定前列腺癌患者预后的方法
公开(公告)号：US20140206623A1
公开(公告)日：2014-07-24
申请号：US14128064
申请日：2012-06-28
申请人： Tommy Andersson , Anders Bjartell
发明人： Tommy Andersson , Anders Bjartell
IPC分类号： A61K38/10 , G01N33/574 , A61K38/08
CPC分类号： A61K38/10 , A61K38/08 , C07K14/475 , G01N33/5088 , G01N33/57434 , G01N2800/52
摘要： The present invention relates to a Wnt5a protein or peptide thereof possessing Wnt5a signaling properties, such as Foxy5, for use in the treatment of prostate cancer, in particular in patients that have undergone or will undergo radical prosteatectomy. The invention also relates to a method for determining a prognosis for a patient having prostate cancer and a kit for performing said method. The method for determining a prognosis for a patient comprises the steps of: evaluating an amount of Wnt5a protein present in at least part of a sample earlier obtained from the patient and determining a sample value corresponding to the evaluated amount; comparing the sample value obtained in step a) with a reference value associated with a reference prognosis; and, if said sample value is higher than said reference value, concluding that the prognosis for said patient is better than said reference prognosis.
摘要翻译：本发明涉及具有Wnt5a信号传导特性的Wnt5a蛋白或其肽，例如Foxy5，用于治疗前列腺癌，特别是在经历或将进行根治性前列腺切除术的患者中。本发明还涉及一种用于确定具有前列腺癌的患者的预后的方法和用于执行所述方法的试剂盒。用于确定患者预后的方法包括以下步骤：评估存在于患者早期获得的样品的至少部分中的Wnt5a蛋白质的量并确定与所述评估量相对应的样品值; 将步骤a）中获得的样品值与参考预后相关的参考值进行比较; 并且如果所述样品值高于所述参考值，则认为所述患者的预后优于所述参考预后。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式